GLP-1 for Fatty Liver Disease (MASLD/MASH)

Metabolic dysfunction-associated steatotic liver disease, MASLD, is what used to be called non-alcoholic fatty liver disease, and it is the commonest chronic liver condition there is — roughly 30% of adults worldwide, rising to about 38% in figures covering 2016 to 2019 [1]. The definition is fat accumulating in liver cells alongside at least one metabolic risk factor — obesity, type 2 diabetes, poor lipids, raised blood pressure — with alcohol ruled out as the cause. Once that fat provokes inflammation, the disease becomes MASH, formerly NASH, and with it come real risks of cirrhosis, liver failure and liver cancer.

What drives it is excess weight and insulin resistance. Visceral fat pours free fatty acids into the portal circulation faster than the liver can burn or export them, so triglycerides accumulate. Insulin resistance compounds it by pushing the liver to manufacture more fat while burning less. The step from simple fat to inflammation adds oxidative stress, failing mitochondria, endotoxins arriving from the gut and inflammatory signals that wake stellate cells and start laying down collagen. That scarring, staged F1 through F4, is the single best histological predictor of dying from liver disease.

For nearly two decades nothing was approved for MASH at all. Treatment meant lifestyle change, controlling the metabolic conditions around it, and managing complications once they arrived. Two approvals in the mid-2020s ended that: resmetirom, which targets the liver's thyroid hormone receptor beta, cleared in March 2024 for non-cirrhotic MASH at fibrosis stage F2 or F3 [6], and then semaglutide at 2.4 mg — the first of this class approved for a liver indication, on the strength of the ESSENCE phase 3 results [4].

The rationale for trying this class here is that its mechanisms converge on the problem from several directions at once: weight loss reduces the fat arriving at the liver, insulin sensitivity improves, hepatic fat manufacture is suppressed through receptors in the liver itself, systemic inflammation falls and gut-derived endotoxin exposure drops. A 2025 meta-analysis of randomized trials confirmed the class significantly improves MASH histology and reduces fibrosis stage against placebo [5].

Semaglutide's phase 2 signal arrived from a randomized trial running 72 weeks across 320 patients whose disease was biopsy-confirmed [2]. Daily semaglutide at 0.4 mg resolved the steatohepatitis without worsening fibrosis in 59% of patients against 17% on placebo, with mean weight down 13% against 1%. The interesting part is what did not reach significance: fibrosis improved by at least one stage in 43% against 33%, a gap the trial was not powered to confirm. Whether a higher dose or longer exposure would turn that into a real anti-fibrotic effect was precisely the question phase 3 existed to answer.

Tirzepatide was tested in the SYNERGY-NASH phase 2 trial [3] in 190 patients with biopsy-defined disease at stages F1 through F3. Resolution without worsening fibrosis reached 44% on 5 mg, 56% on 10 mg and 62% on 15 mg, against 10% for placebo. Fibrosis improved by at least a stage in 51% of the two higher-dose groups against 30% on placebo. The dose-response gradient, as much as the absolute numbers, is what justified taking it into phase 3.

ESSENCE [4] is the pivotal trial: 1,197 patients with biopsy-defined MASH at fibrosis stage F2 or F3, randomized two-to-one to weekly semaglutide 2.4 mg or placebo. The planned interim analysis at week 72, covering 800 patients, found steatohepatitis resolved without worsening fibrosis in 62.9% against 34.3% — a gap of 28.7 percentage points. Fibrosis reduced without worsening steatohepatitis in 36.8% against 22.4%. Achieving both at once, which is the outcome that matters most, occurred in 32.7% against 16.1%. Mean weight fell 10.5% against 2.0%. Those results produced the approval that made this the first drug of its class licensed for a liver disease.

The approval covers adults with MASH at fibrosis stage F2 or F3, and the diagnosis it rests on is a biopsy showing both steatohepatitis — lobular inflammation and ballooned hepatocytes — and non-cirrhotic fibrosis at one of those two stages. Non-invasive tests, whether elastography, serum panels or MR elastography, can screen and can track response, but staging by biopsy is what establishes eligibility as the indication is currently written.

A great many people in this position also qualify on weight grounds — a BMI of 30 or above, or 27 with diabetes, raised blood pressure, poor lipids or heart disease alongside. Where both apply they reinforce each other rather than competing. Anyone with type 2 diabetes taking semaglutide at diabetes doses will also see hepatic fat improve, though that product is not approved for MASH. Tirzepatide has strong phase 2 evidence and phase 3 work underway; using it for the liver today is off-label.

Cirrhosis, stage F4, sits outside all of this — neither ESSENCE nor SYNERGY-NASH enrolled those patients, and neither approval covers them. That is specialist hepatology territory: portal hypertension, varices, cancer surveillance and transplant assessment where appropriate. Resmetirom holds a parallel approval at the same non-cirrhotic F2-F3 stages, and depending on circumstances may be used alongside semaglutide or instead of it.

Stomach side effects — nausea, vomiting, constipation, diarrhea — were commoner on the drug than on placebo in ESSENCE, as they are everywhere else in this class. They cluster while the dose is climbing and generally ease with continued use. The usual mitigations apply: lowest starting dose, slow escalation, smaller meals, less fat. Most people complete titration without stopping, though anyone with significant pre-existing gastroparesis warrants closer watching.

Confirming the fibrosis stage before starting matters twice over — for choosing the right patients, and for documenting the case to a payer. It also matters afterward, because whether treatment is working cannot be judged without a repeat biopsy or validated non-invasive testing. ESSENCE reported at 72 weeks; the questions that actually decide value — does this prevent cirrhosis, reduce liver events, extend life — wait on its prespecified follow-up out to 240 weeks.

This class treats the liver through metabolic routes: weight, insulin sensitivity, hepatic fat. It does not directly switch off the stellate cells that lay down scar tissue, which is what the emerging anti-fibrotic drugs are aimed at. And alcohol undercuts all of it — continuing to drink, even moderately, blunts the hepatic benefit and can drive fibrosis onward regardless of what is prescribed. Diet quality, abstinence, activity and the surrounding metabolic conditions all remain part of the treatment, with the drug as a powerful addition rather than a replacement for any of them.